<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02824393</url>
  </required_header>
  <id_info>
    <org_study_id>TUBITAK-1001-215S612</org_study_id>
    <nct_id>NCT02824393</nct_id>
  </id_info>
  <brief_title>Experimental Autologous Mesenchymal Stem Cell Therapy in Treatment of Chronic Autoimmune Urticaria</brief_title>
  <official_title>Experimental Autologous Mesenchymal Stem Cell Therapy in Treatment of Chronic Autoimmune Urticaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celal Bayar University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Scientific and Technological Research Council of Turkey</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Acıbadem Labcell</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Celal Bayar University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether autologous adipose tissue derived Mesenchymal
      Stem Cells of treatment for chronic autoimmune urticaria is safe and effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic urticaria is a distressful disease, which negatively affects the quality of life.
      Pathogenesis isn't exactly clear, treatment is relatively palliative and results are usually
      suboptimal. 30-40% of the patients have autoimmune origin. Patients are forced to use
      immunosuppressive treatments which have systemic effects. Some of the treatments have effects
      as severe as the disease itself.

      Mesenchymal stem cells (MSCs) are the most common used cells in clinical trials. These cells
      can provide efficient immunosuppression in severe conditions like immunosuppressive resistant
      Graft versus Host Disease. With this study at the first time and quite a different approach
      from conventional treatment, it will be tried an experimental treatment that used in the MSCs
      for the chronic autoimmune urticaria patients without of definitive treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2017</start_date>
  <completion_date type="Anticipated">June 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in weekly urticaria activity scores.</measure>
    <time_frame>6 months</time_frame>
    <description>The weekly urticaria activity scores will be assessed according to European Academy of Allergy and Clinical Immunology (EAACI) / Global Allergy and Asthma European Network (GALEN) guidelines.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Follow-up of the mesenchymal stem cell treatment-related side effects according to World Health Organisation (WHO) Toxicity Grading Scale for Determining The Severity of Adverse Events.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in the ratios of peripheral blood cluster of differentiation 4 (CD4) T cell subsets.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in ratios of peripheral blood inflammatory and anti-inflammatory cytokines.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in the levels of peripheral blood anti-FcεRI autoantibody</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Urticaria</condition>
  <condition>Autoimmune Diseases</condition>
  <condition>Immune System Diseases</condition>
  <condition>Skin Diseases</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patients who treated with the conventional therapy for urticaria, but not treat with mesenchymal stem cell.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous mesenchymal stem cell</intervention_name>
    <description>Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.</description>
    <arm_group_label>Mesenchymal stem cell</arm_group_label>
    <other_name>Autologous adipose tissue derived mesenchymal stem cell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed with chronic autoimmune urticaria (at least six months before)

          2. Patients who have &gt;20 and over of urticaria activity score [according to European
             Academy of Allergy and Clinical Immunology (EAACI) / Global Allergy and Asthma
             European Network (GALEN) guidelines].

          3. Patients who capable of own daily findings record.

          4. Patients who could not be controlled despite the use of a treatment agent in the
             fourth step for 3 months (according to EAACI / GALEN guidelines).

        Exclusion Criteria:

          1. Patients who have heart, liver or renal failure.

          2. Patients who have epilepsy, cerebrovascular or ischemic attack.

          3. Patients who have atopic dermatitis or another underlying itchy skin disease.

          4. Patients who have parasitic infection.

          5. Patients who have antibiotic allergy.

          6. History of malignancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alper Tunga Özdemir, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ege University, Institute of Health Sciences, Department of Stem Cell, Izmir/TURKEY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ercüment Ovalı, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Acıbadem Labcell, Istanbul/TURKEY</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cengiz Kırmaz, Prof.Dr.</last_name>
    <phone>+90 532 415 0831</phone>
    <email>ckirmaz@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rabia Bilge Özgül Özdemir, MD</last_name>
    <phone>+90 505 391 1471</phone>
    <email>rabiabilgeozgul@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Celal Bayar University, Medical School</name>
      <address>
        <city>Manisa</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cengiz Kırmaz, Prof. Dr.</last_name>
      <phone>+90 532 415 0831</phone>
      <email>ckirmaz@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Rabia Bilge Özgül Özdemir, MD</last_name>
      <phone>+90 505 391 14 71</phone>
      <phone_ext>Özgül Özdemir</phone_ext>
      <email>rabiabilgeozgul@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alper Tunga Özdemir, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ercüment Ovalı, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ercüment Ölmez, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hakan Kerem, Associate Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2016</study_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Celal Bayar University</investigator_affiliation>
    <investigator_full_name>Cengiz Kırmaz</investigator_full_name>
    <investigator_title>Professor Doctor (MD)</investigator_title>
  </responsible_party>
  <keyword>Mesenchymal stem cell</keyword>
  <keyword>Chronic autoimmune urticaria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

